# Sarepta Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Sarepta Therapeutics, Inc.).

## Overview

Sarepta Therapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy, and other genetic medicine modalities for rare diseases. Its portfolio includes approved Duchenne muscular dystrophy products and a pipeline spanning Duchenne, LGMD, and other neuromuscular and genetic disorders.

## Products & services

• EXONDYS 51 (eteplirsen) for Duchenne muscular dystrophy
• VYONDYS 53 (golodirsen) for Duchenne muscular dystrophy
• AMONDYS 45 (casimersen) for Duchenne muscular dystrophy
• ELEVIDYS gene therapy for Duchenne muscular dystrophy
• RNA-targeted and siRNA-based rare disease therapeutics
• Gene therapy and genetic medicine development programs

- **Duchenne PMO therapies** (55%) — Exon-skipping therapies for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, and AMONDYS 45.
- **Duchenne gene therapy** (35%) — ELEVIDYS, a gene therapy product for Duchenne muscular dystrophy.
- **Collaboration and royalty revenue** (8%) — Revenue from Roche collaboration, supply, and royalties tied to ELEVIDYS outside the U.S.
- **Pipeline and partnered programs** (2%) — Precommercial RNA, siRNA, and gene therapy programs for rare neuromuscular and genetic diseases.

- EXONDYS 51 (eteplirsen)
- VYONDYS 53 (golodirsen)
- AMONDYS 45 (casimersen)
- ELEVIDYS
- RNA-targeted therapeutics
- siRNA knockdown therapies
- Gene therapy programs

## Customers

Sarepta sells primarily to patients with rare neuromuscular diseases through specialty pharmacy, home infusion, and hospital channels, with reimbursement decisions made by government and private payors. Its commercial products are used by physicians and care teams treating Duchenne muscular dystrophy, while its partnered and precommercial programs are aimed at future patients in additional rare disease indications.

- **Duchenne muscular dystrophy patients** (primary) — Buyers are patients through their care providers; they use approved PMO therapies and ELEVIDYS to treat Duchenne.
- **Hospitals and infusion centers** (primary) — They administer ELEVIDYS and handle infusion-based treatment delivery.
- **Specialty pharmacies and distributors** (primary) — They distribute PMO products to patients and hospitals in the U.S.
- **Payors and reimbursement systems** (primary) — They do not buy the drug directly but determine access and timing of payment.
- **International partner channels** (secondary) — Roche and other distributors support ex-U.S. supply and commercialization of ELEVIDYS.

- Patients with Duchenne muscular dystrophy receiving specialty therapies
- Hospitals and hospital outpatient clinics administering ELEVIDYS
- Home infusion specialty pharmacies distributing PMO products
- Government and private payors determining reimbursement access
- Physicians and neuromuscular specialists prescribing rare disease therapies

## Geography

Sarepta is headquartered in the United States and generates most commercial activity through U.S. specialty distribution and hospital channels. Outside the U.S., it uses partners and third-party distributors for precommercial access and for ELEVIDYS supply under the Roche collaboration, making international commercialization dependent on local approvals and partner execution.

- Headquartered in the United States
- U.S. sales run through specialty pharmacy and hospital channels
- Ex-U.S. access relies on third-party distributors and partners
- Roche supplies and commercializes ELEVIDYS in approved territories
- International expansion depends on local regulatory approvals

## Strategy

Sarepta’s strategy centers on extending its Duchenne franchise while broadening its RNA and gene-therapy platform into additional rare diseases. It also relies on manufacturing partnerships and collaborations, especially with Roche and Arrowhead, to support clinical development, supply, and future commercialization.

- **Grow the Duchenne franchise** (short-term) — Duchenne is the core commercial base and supports the company’s brand, infrastructure, and cash generation.
- **Advance gene therapy and RNA pipeline** (medium-term) — New modalities and indications can broaden the addressable market beyond current approved products.
- **Scale manufacturing and supply partnerships** (short-term) — Complex biologics and gene therapies require reliable third-party capacity and quality control.
- **Expand ex-U.S. commercialization** (medium-term) — International approvals and partner-led distribution can extend product reach without building full direct infrastructure everywhere.

- Expand the Duchenne franchise with approved products and ELEVIDYS
- Advance RNA, siRNA, and gene therapy pipeline programs
- Use partnerships to scale manufacturing and distribution
- Pursue additional rare-disease indications beyond Duchenne
- Leverage collaboration and royalty economics outside the U.S.

## Risks

Sarepta depends heavily on a small number of commercial products, so product performance, safety data, reimbursement, and regulatory outcomes can materially affect results. Its gene-therapy and RNA platforms also face manufacturing complexity, supply-chain concentration, intellectual-property disputes, and clinical-development uncertainty typical of rare-disease biopharma.

- **Commercial concentration in Duchenne products** [high] — A large share of value depends on a narrow set of approved therapies and one disease area.
- **Regulatory and safety risk** [high] — Accelerated approval status and label perception depend on ongoing clinical and safety evidence.
- **Reimbursement and access risk** [high] — Specialty drugs require timely payor approval and favorable coverage to convert demand into sales.
- **Manufacturing and supply-chain disruption** [high] — Gene therapies and PMO products rely on third-party manufacturing, testing, and single-source inputs.
- **Competitive and IP risk** [medium] — Other RNA, gene therapy, and gene editing programs may compete in the same rare-disease markets.

- Heavy dependence on a few Duchenne products
- Safety or efficacy data can affect approvals and uptake
- Reimbursement and prior authorization can delay access
- Gene therapy manufacturing is complex and supply constrained
- IP disputes and competitor programs can limit market share

## Accounting

Inventory valuation is a critical estimate because Sarepta capitalizes approved-product inventory and must write it down when demand, quality, or realizability changes. Revenue also includes collaboration, contract manufacturing, and royalty streams tied to Roche, so timing and classification of those arrangements can materially affect reported results; clinical trial commitments and income tax estimates are also important judgment areas.

- **Inventory valuation** — Cost of sales and gross margin
- **Collaboration and royalty revenue** — Revenue timing and mix
- **Clinical trial commitments** — Operating expense and cash planning
- **Income tax estimates** — Tax provision

- Inventory capitalization and write-downs can move cost of sales
- Approved-product inventory may be expensed into R&D if used clinically
- Collaboration revenue depends on Roche arrangement terms
- Royalty and contract manufacturing revenue timing affects quarterly results
- Income tax and clinical trial commitments require significant estimates

---

*Last updated: 2026-04-29T04:57:35.239044+00:00*